Trials / Completed
CompletedNCT00089570
Study of Terlipressin Versus Placebo to Treat Hepatorenal Syndrome Type 1
A Double-Blind, Randomized, Placebo-Controlled, Multicenter Phase III Study of Intravenous Terlipressin in Patients With Hepatorenal Syndrome Type 1
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 112 (actual)
- Sponsor
- Mallinckrodt · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine whether terlipressin is safe and effective in the treatment of patients with hepatorenal syndrome (HRS) type 1 when compared to placebo.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | terlipressin | |
| DRUG | Placebo |
Timeline
- Start date
- 2004-06-01
- Primary completion
- 2006-03-01
- Completion
- 2006-09-01
- First posted
- 2004-08-09
- Last updated
- 2017-10-27
Locations
37 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00089570. Inclusion in this directory is not an endorsement.